Spoken Alpha
ROIV
Roivant Sciences Ltd.
Overview
Roivant Sciences designs and develops biopharmaceutical medicines through a subsidiary-based "Vant" model. The company's pipeline includes brepocitinib for autoimmune skin and eye diseases, IMVT-1402 for IgG-mediated autoimmune conditions, and mosliciguat for pulmonary hypertension.
Roivant Sciences Ltd is a Healthcare company operating in Biotechnology with a $23.17B market cap.
ROIV beat consensus EPS by 1.0% in Q2 FY2026, reported Aug 9, 2026.
18 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2025Earnings2026-05-2017 Q&A exchanges
- Q3 FY2025Earnings2026-02-0616 Q&A exchanges
- Q2 FY2025Earnings2026-01-0816 Q&A exchanges
- Q1 FY2025Earnings2025-08-1114 Q&A exchanges
- Q4 FY2024Earnings2025-05-2919 Q&A exchanges
- Q3 FY2024Earnings2025-02-1016 Q&A exchanges
- Q2 FY2024Earnings2024-11-1213 Q&A exchanges
- Q1 FY2024Earnings2024-08-0918 Q&A exchanges
- Q4 FY2023Earnings2024-05-3018 Q&A exchanges
- Q3 FY2023Earnings2024-02-1314 Q&A exchanges
- Q2 FY2023Earnings2023-11-1324 Q&A exchanges
- Q1 FY2023Earnings2023-08-1423 Q&A exchanges
- Q4 FY2022Earnings2023-06-2815 Q&A exchanges
- Q3 FY2022Earnings2023-02-1315 Q&A exchanges
- Q2 FY2022Earnings2022-11-1413 Q&A exchanges
- Q1 FY2022Earnings2022-08-1517 Q&A exchanges
- Q4 FY2021Earnings2022-06-2820 Q&A exchanges
- Q2 FY2021Earnings2021-11-1515 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-09EPS$0.00 vs $-0.23+100.0%Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-09 | $0.00 | $-0.23 | +100.0% | — | — | — | EODHD |
Source: EODHD. ROIV reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ROIV's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $2.72 | $3.13 | -13.0% | +2.8% | +5.3% |
| Q4 FY2025 | $2.62 | $3.38 | -22.5% | -0.1% | +2.2% |
| Q3 FY2025 | $2.85 | $3.31 | -13.8% | -9.1% | -11.8% |
| Q2 FY2025 | $2.68 | $3.42 | -21.7% | -5.9% | -7.7% |
| Q1 FY2024 | $2.90 | $3.25 | -10.7% | -0.7% | +1.2% |
| Q4 FY2024 | $2.88 | $3.44 | -16.4% | -2.2% | -4.8% |
| Q3 FY2024 | $3.14 | $3.43 | -8.6% | -8.4% | -10.1% |
| Q2 FY2024 | $2.64 | $3.30 | -20.0% | -6.5% | -5.3% |
| Q1 FY2023 | $2.85 | $3.34 | -14.7% | -8.1% | -6.7% |
| Q4 FY2023 | $2.84 | $3.40 | -16.5% | -0.6% | +1.6% |
Guidance change history
Sample- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
- Q1 FY2024Lowered2024-04-15
- Q4 FY2024Lowered2024-13-15
- Q3 FY2024Lowered2024-10-15
- Q2 FY2024Lowered2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Eric VenkerCEO6 mono recorded callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last guidance raise Q2 FY2025
- Matthew GlineCEO6 mo18 callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last call held guidance Q3 FY2025
- Richard PulikCFO6 mo4 callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last call held guidance Q2 FY2025
- Frank TortiPresident6 mo4 callsCurrentSample
PRESIDENT since 2025 • 2/2 beats (100%) • last call held guidance Q2 FY2025
- Mayukh SukhatmePresident6 mo7 callsCurrentSample
PRESIDENT since 2025 • 1/2 beats (50%) • guidance suspended Q1 FY2025
- Jennifer HumesChief Accounting Officer3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q2 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ROIV.
$ curl https://api.spokenalpha.com/v1/companies/ROIVFAQ
Frequently asked about ROIV
Where can I find Roivant Sciences Ltd.'s (ROIV) earnings call transcripts?
Spoken Alpha indexes ROIV's earnings call transcripts at https://spokenalpha.com/companies/ROIV. Each call links to attributed speakers and parsed analyst Q&A. Roivant Sciences Ltd.'s own investor relations page is at https://investor.roivant.com/.
When was Roivant Sciences Ltd.'s most recent earnings call?
Roivant Sciences Ltd. (ROIV) held its most recent earnings call on 2026-05-20, covering fiscal Q4 2025.
What sector is ROIV in?
Roivant Sciences Ltd. (ROIV) operates in the Healthcare sector (Biotechnology industry).